Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804491 | 0.91 | PPARG (0.37) | PPARGPPARACSF1RPDE4BPDE4A | |
| SCHEMBL19804730 | 0.90 | MMP2 (0.38) | PPARGPPARACSF1RTSHRRAB9A | |
| SCHEMBL19804400 | 0.89 | PPARG (0.38) | PPARGPPARACSF1RPDE4BPDE4A | |
| SCHEMBL19804072 | 0.87 | CSF1R (0.40) | PPARGPPARACSF1RPDE4BPDE4A | |
| SCHEMBL19804061 | 0.87 | SLC6A9 (0.40) | PPARGPPARACSF1RMCHR1TSHR | |
| SCHEMBL19796620 | 0.86 | PPARG (0.35) | PPARGPPARACSF1RBRD4TSHR | |
| SCHEMBL19804365 | 0.85 | FFAR4 (0.33) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL19804030 | 0.84 | ACMSD (0.32) | PPARGPPARAPDE4BPDE4APDE4C | |
| SCHEMBL19804357 | 0.84 | MMP2 (0.39) | PPARGPPARATSHRRAB9APPARD | |
| SCHEMBL19804064 | 0.83 | CYP3A4 (0.43) | PPARGPPARACSF1RPPARDPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | PPARG 3314/4885PPARA 3672/4885CSF1R 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.